{"id":957740,"date":"2026-05-04T16:20:33","date_gmt":"2026-05-04T20:20:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/"},"modified":"2026-05-04T16:20:33","modified_gmt":"2026-05-04T20:20:33","slug":"capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/","title":{"rendered":"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12"},"content":{"rendered":"
\n

\u2013 Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET \u2013<\/p>\n

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics<\/a>\u00a0(NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day.<\/p>\n\n\n\n\n\n\n
\n Title:<\/p>\n

<\/strong>\n <\/td>\n

Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast<\/p>\n<\/td>\n<\/tr>\n
\n Date:<\/p>\n

<\/strong>\n <\/td>\n

Tuesday, May 12, 2026<\/p>\n<\/td>\n<\/tr>\n
\n Time:<\/p>\n

<\/strong>\n <\/td>\n

4:30 p.m. ET<\/p>\n<\/td>\n<\/tr>\n
\n Call Details:<\/p>\n

<\/strong>\n <\/td>\n

Toll-Free: 1-800-717-1738
International: 1-646-307-1865
Conference ID: 60968<\/p>\n

Participants may dial in using the numbers above and ask to be joined to the call, or use the\u00a0Call Me\u2122<\/a> link for instant telephone access to the event.<\/p>\n<\/td>\n<\/tr>\n

\n Webcast:<\/strong>\n <\/td>\n\n Click Here<\/a>\n <\/td>\n<\/tr>\n<\/table>\n

\n
A replay of the webcast will be available shortly after the conclusion of the live event and will be accessible in the Investors section of the Company\u2019s website at www.capricor.com<\/a>.<\/p>\n

\n
\n About Capricor Therapeutics<\/em>
\n <\/strong>\n <\/p>\n

Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy that is currently in late-stage development for the treatment of Duchenne muscular dystrophy (DMD). Extensive preclinical and clinical data have demonstrated Deramiocel\u2019s potent immunomodulatory and anti-fibrotic effects in helping to preserve cardiac and skeletal muscle function in DMD. Capricor is also leveraging the power of its exosome technology, using its proprietary StealthX\u2122 platform in preclinical development focused on vaccinology and the targeted delivery of oligonucleotides, proteins, and small-molecule therapeutics, with the potential to treat and prevent a wide range of diseases. At Capricor, we are committed to pushing the boundaries of possibility and forging a path toward transformative treatments for those in need. For more information, visit\u00a0capricor.com<\/a>, and follow Capricor on\u00a0Facebook<\/a>,\u00a0Instagram<\/a>\u00a0and\u00a0X<\/a>.<\/p>\n

\n
\n Cautionary Note Regarding Forward-Looking Statements<\/em>
\n <\/strong>\n <\/p>\n

Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor\u2019s product candidates; the initiation, conduct, size, timing and results of clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including future interactions with regulatory authorities and the ability to obtain regulatory approvals or otherwise bring products to market; manufacturing capabilities; dates for regulatory meetings; the potential that required regulatory inspections may be delayed or not be successful which would delay or prevent product approval; the ability to achieve product milestones and to receive milestone payments from commercial partners; and any other statements about Capricor\u2019s management team\u2019s future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words \u201cbelieves,\u201d \u201cplans,\u201d \u201ccould,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor\u2019s business is set forth in Capricor\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 17, 2026. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.<\/p>\n

Capricor has entered into an agreement for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan with Nippon Shinyaku Co., Ltd. (U.S. subsidiary: NS Pharma, Inc.), subject to applicable regulatory approvals. Deramiocel and the StealthX\u2122 vaccine are investigational candidates and have not been approved for commercial use in any indication.<\/p>\n

\n
\n For more information, please contact:<\/em>
\n <\/strong>\n <\/p>\n

\n Capricor Media Contact:<\/strong>
\n
Caitlin Kasunich
KCSA Strategic Communications
ckasunich@kcsa.com<\/a>
212.896.1241<\/p>\n

\n Capricor Company Contact:<\/strong>
\n
AJ Bergmann, Chief Financial Officer
abergmann@capricor.com<\/a>
858.727.1755<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET \u2013 SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics\u00a0(NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title: Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Tuesday, May 12, 2026 Time: 4:30 p.m. ET Call Details: Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 60968 Participants may dial in using the … <\/p>\n

Continue reading “Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-957740","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCapricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET \u2013 SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics\u00a0(NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title: Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Tuesday, May 12, 2026 Time: 4:30 p.m. ET Call Details: Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 60968 Participants may dial in using the … Continue reading "Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-04T20:20:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12\",\"datePublished\":\"2026-05-04T20:20:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/\"},\"wordCount\":701,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/\",\"name\":\"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==\",\"datePublished\":\"2026-05-04T20:20:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/","og_locale":"en_US","og_type":"article","og_title":"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - Market Newsdesk","og_description":"\u2013 Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET \u2013 SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) — Capricor Therapeutics\u00a0(NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title: Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and Webcast Date: Tuesday, May 12, 2026 Time: 4:30 p.m. ET Call Details: Toll-Free: 1-800-717-1738International: 1-646-307-1865Conference ID: 60968 Participants may dial in using the … Continue reading \"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-04T20:20:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12","datePublished":"2026-05-04T20:20:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/"},"wordCount":701,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/","name":"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==","datePublished":"2026-05-04T20:20:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMjYwMiM3NTgyMDI5IzUwMDA2ODU2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=957740"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/957740\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=957740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=957740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=957740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}